Background Endogenous or iatrogenic antitumour immune responses can improve the
course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour …

Background Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and
most patients ultimately relapse. Lenalidomide, an immunomodulatory agent, is effective as …

Proteasome inhibition with bortezomib is a validated approach to the treatment of multiple
myeloma, but drug resistance often emerges and limits its utility in the retreatment setting. To …

Purpose: Development of chemoresistance, poor prognosis, and metastasis often renders
the current treatments for colorectal cancer (CRC) ineffective. Whether ursolic acid, a …

Background Tumor suppressor gene TUSC2/FUS1 (TUSC2) is frequently inactivated early
in lung cancer development. TUSC2 mediates apoptosis in cancer cells but not normal cells …

Motivation: Analyzing data from multi-platform genomics experiments combined with patients’
clinical outcomes helps us understand the complex biological processes that characterize …

Separase is an endopeptidase that separates sister chromatids by cleaving cohesin Rad21
during the metaphase-to-anaphase transition. Conditional expression of Separase in …

With only 536 cases and 11 fatalities, India took the historic decision of a 21-day national
lockdown on March 25. The lockdown was first extended to May 3 soon after the analysis of this …

Despite tremendous progress in precision oncology, adaptive resistance mechanisms limit
the long-term effectiveness of molecularly targeted agents. Here we evaluated the …

Resistance of myeloma to lenalidomide is an emerging clinical problem, and though it has
been associated in part with activation of Wnt/β-catenin signaling, the mediators of this …